Prostatype Genomics

Prostatype Genomics AB ("Prostatype Genomics" or the "Company") rights issue of units, with a subscription period ending on September 2, 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is 18 September 2024, and the stop day is 20 September 2024. The first day of trading in warrants of series TO 4 is 24 September 2024.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, GREAT BRITAIN, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTED WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

In August/September 2024, Prostatype Genomics carried out a rights issue which provided the Company with approximately SEK 35.7 million before issue costs. The rights issue has now been registered at the Swedish Companies Registration Office and the last day of trading in BTU is 18 September 2024 and the cut-off date is 20 September 2024. Shares and warrants of series TO 4 are expected to be distributed to the VP account/depot on 24 September 2024.

After the Swedish Companies Registration Office's registration of the rights issue and the directed issue to guarantors, the total number of shares in the Company amounts to 5,148,351,416 shares and the share capital to SEK 51,483,514.16. In addition, there are a total of 1,663,016,092 outstanding warrants of series TO 4. The first day of trading in warrants of series TO 4 is 24 September 2024.

Advisors
Prostatype Genomics has mandated Gemstone Capital A/S as financial advisor, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as settlement agent in connection with the Rights Issue.

For further information about Prostatype Genomics, please contact:
Fredrik Rickman (formerly Persson), CEO Prostatype Genomics AB,
Telephone: +46 (0) 73 049 77 01,
E-mail: fredrik.rickman@prostatypegenomics.com

Certified Advisors
Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, certifiedadviser@carnegie.se

About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Important information
This press release does not constitute an offer to acquire, subscribe or otherwise trade in shares, warrants, unit rights, BTU or other securities in Prostatype Genomics AB investors must not subscribe or acquire any securities other than on the basis of the information in the prospectus that has been published before the start of the subscription period in the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden.

This press release may not be published, published or distributed, directly or indirectly, in or to the United States, Australia, Great Britain, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be illegal. This press release also does not constitute an offer to sell new shares, warrants, unit rights, BTU or other securities to any person in a jurisdiction where it would not be permitted to make such an offer to such a person or where such action would require a prospectus, additional registration or other measures than under Swedish law. The prospectus, the notification form and other documents relating to the Rights Issue may not be distributed in or to any country where such distribution or the Rights Issue requires actions as stated in the preceding sentence or where they would be contrary to regulations in such country. Actions contrary to this instruction may constitute a violation of applicable securities legislation.

No shares, warrants, unit rights, BTUs or other securities have been or will be registered under the United States Securities Act of 1933, as amended ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, subscribed , is exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or through a transaction not subject to, the registration requirements of the Securities Act and in accordance with the securities laws of the relevant state or other jurisdiction in the United States.

This press release may contain certain forward-looking information that reflects the Company's current view of future events as well as financial and operational development. Words such as "intends", "estimates", "expects", "may", "plans", "believes", "estimates" and other expressions that imply indications or predictions of future developments or trends, and are not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking information is not a guarantee of future performance or development, and actual outcomes may differ materially from what is stated in forward-looking information. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Nasdaq First North Growth Market regulations.